Early Phase 1 N=54 Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Breast Cancer · Triple Negative Breast Cancer · Hormone Receptor Negative Neoplasm
Primary: PD-1 Expression — 0; 0; 0; 0 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=252 Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine Without Aura · Migraine With Aura
Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants
Phase 3 N=502 Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Advanced Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole — 63.2; 57.7; 56.5; 60.8…
Phase 2 N=61 Idebenone for Primary Progressive Multiple Sclerosis
Multiple Sclerosis · Primary Progressive Multiple Sclerosis
Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year
N/A N=174 Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Infant, Premature · Premature Birth
Primary: Preterm Birth — 29; 30 Participants
Phase 3 N=45 Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
Hypoglycemia · Diabetes Mellitus, Type 1
Primary: Time to Plasma Glucose Recovery. — 10.0; 35.0 minutes — p=<0.0001
Phase 4 N=80 Spinal or Epidural Fentanyl or Sufentanil for Labour Pain in Early Phase of the Labour
Labor Pain
Primary: Change of Maximum Pain During Contraction at 20 Minutes After the Study Drug Delivery — 60; 36; 67; 42 mm
Phase 2 N=87 A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Neoplasms
Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) — 1; 1; 1; 5 Participants
Phase 3 N=56 Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder
PostTraumatic Stress Disorder
Primary: Level of Interleukin-6 (IL6) — 0.88; 0.84; 1.77; 2.11 pg/ml
N/A N=1,499 Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
HIV
Primary: Severe Events — 3.3; 4.2; 4.2 Events per 100 participant-years — p=<=0.05
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Phase 2 N=90 NAC for Treating Comorbid PTSD and SUD
Posttraumatic Stress Disorder (PTSD) · Alcohol Use Disorder (AUD) · Substance Use Disorder (SUD)
Primary: Change in Alcohol Use Disorder Severity — -2.65; -2.82 drinking days reduction
N/A N=62 Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents
Polypharmacy · Inappropriate Prescribing
Primary: Number of Inappropriate Medication at Follow-up — 4.35; 4.85 drugs — p=0.723
N/A N=68 A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer
Prostate Cancer
Primary: Adverse Events — 0; 0 Adverse Events
N/A N=1,304 Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"
A History of Gastric or Duodenal Ulcers
Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 0.71 Percentage of Participants